Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Progen Of Australia Sees Daylight With Liver Cancer Drug Set For Trial

This article was originally published in PharmAsia News

Executive Summary

Australia's Progen Phamaceuticals may have overcome its boardroom battle with an agreement to repurchase shares to neutralize shareholder complaints. Some shareholders revolted when Progen sought to merge with another company and spent heavily to promote a liver cancer drug now expected to begin trials in Taiwan. The proposed merger collapsed and the company was able to turn back a pair of coup attempts. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts